April 02, 2026 12:23 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead

Government to roll out new drug for treatment of drug-resistant TB

| | Mar 21, 2016, at 08:09 pm
New Delhi, Mar 21 (IBNS) The central government is launching a drug called Bedaquiline on Monday for the treatment of multi-drug resistant tuberculosis (MDR TB) and extensively drug resistant tuberculosis (XDR TB), according to media reports.
Dubbed a 'miracle drug',  Bedaquiline (trade name Sirturo) is the first TB drug to be approved by Food and Drug Administration (FDA) in over 40 years.
 
The project is part of a coordinated programme between the government and Johnson & Johnson and has been rolled out under the Revised National Tuberculosis Control Programme; Janssen, a pharma unit under Johnson & Johnson  has manufactured the drug.
 
The drug will be made available in six public hospitals in Delhi, Mumbai, Chennai, Guwahati and Ahmedabad, according to reports.
 
In an exclusive interview to Times of India, Sanjiv Navangul, Janssen India MD, said, "We are ready with the roll-out of the drug through the government-run control programme, for which 600 patients will be enrolled across the country, over the next six to nine months, after the required tests. Upon the review of clinical data after two years, the access programme will be expanded nationwide."
 
As per World Health Organisation (WHO) Global Tuberculosis Report 2015, deaths due to TB were estimated in India to be 2,20,000 in 2014, which is higher than any other country.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.